Disease mechanisms regarding hypertrophic cardiomyopathy (HCM) are largely unknown and disease onset varies. Sarcomere mutations might induce energy depletion for which until now there is no direct evidence at sarcomere level in human HCM. This study investigated if mutations in genes encoding myosin binding protein C (MYBPC3) and myosin heavy chain (MYH7) underlie changes in the energetic cost of contraction in the development of human HCM disease.
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetically inherited cardiac disease with an incidence of 0.2%, characterized by asymmetric hypertrophy of the left ventricle in the absence of other cardiac or systemic diseases. 1 Since its first description in 1957 as a noncoronary heart muscle disease of unknown aetiology 2 , the major breakthrough with respect to its cause was the discovery of the first mutation in the gene (MYH7) encoding the sarcomeric protein β-myosin heavy chain in 1990. 3 In subsequent years, many HCM-causing mutations have been found, mostly in genes encoding sarcomeric proteins. 4 Despite the discovery of multiple genetic defects, insight into the pathophysiological mechanisms that lead from sarcomere mutation to HCM phenotype are limited. This is partly due to the clinical heterogeneity of HCM, ranging from asymptomatic individuals to sudden cardiac arrest or development of overt cardiomyopathy at young age. Moreover, several clinical studies observed differences in disease onset between patients with mutations in the most frequently affected thick filament genes, MYH7 and MYBPC3 (encoding cardiac myosin binding protein C: cMyBP-C), indicative for gene-specific differences in the clinical course of HCM. [5] [6] [7] [8] [9] A better understanding of the sarcomeric deficits, which initiate development of HCM, may explain phenotypic differences and improve treatment at an early stage.
A complex chain of events may lead from defective sarcomeres to contractile dysfunction and cardiac remodelling. An attractive hypothesis that has been put forward is the energy depletion hypothesis, which originally was shown to be of importance in the development of heart failure. [10] [11] [12] [13] The association of energy depletion with HCM mutations 14, 15 is based on observations in both in vivo transgenic mouse models [16] [17] [18] [19] and in vivo human studies. [20] [21] [22] Using magnetic resonance spectroscopy, a reduction in the cardiac PCr to ATP ratio, a measure of energetic status, was found both in mice with a mutation in the gene encoding the cardiac thin filament protein troponin T (TNNT2) 16, 17 and in those harboring the MYH7 R403Q mutation 18 compared with controls. Similarly, PCr/ATP was found to be reduced in HCM patients with left ventricular hypertrophy (LVH). [20] [21] [22] [23] Interestingly, a reduction in PCr/ATP was already present in mutation carriers without LVH. 20 Moreover, a recent study in MYBPC3 mutation carriers without LVH showed reduced myocardial efficiency compared with controls, evident from a reduced ratio between cardiac work and oxygen consumption. 23 These studies suggest that changes in myocardial efficiency may represent a primary trigger of cardiac dysfunction and remodelling in HCM. To date, however, there is no direct proof of inefficient ATPase activity at the level of the cardiac sarcomere in human HCM.
To investigate whether sarcomere mutations increase an energetic cost of contraction, in vitro ATPase activity was measured during isometric sarcomere contraction in demembranated multicellular muscle strips from manifest sarcomere mutation-positive HCM patients. Sarcomere mutation-negative HCM patients served as a control group as they have the same phenotype as mutation-positive HCM patients, evident from similar left ventricular (LV) remodelling in the absence of a sarcomeric gene mutation. Moreover, to assess if gene-specific variation may underlie a difference in disease onset, comparisons were made between MYBPC3 and MYH7 mutations in the in vitro and in vivo study, using [ 11 C]-acetate positron emission tomography (PET) and cardiovascular magnetic resonance (CMR) imaging studies, in pre-hypertrophic mutation carriers compared with the healthy control subject.
Methods

In vitro analysis Cardiac tissue of manifest HCM patients
Cardiac tissue was obtained from the LV interventricular septum of 26 HCM patients during myectomy surgery relieving LV outflow tract obstruction or after heart transplantation (3 patients). Eleven patients harbored a mutation in MYBPC3, 9 in MYH7 and 6 did not carry a sarcomeric gene mutation after screening 8 most commonly involved genes. The latter, sarcomere mutation-negative patient group (HCM smn ) served as control. Specific mutation and clinical data of patients are provided in Table 1 . The study protocol was in agreement with principles outlined in the Declaration of Helsinki and it was approved by the local Medical Ethics Review Committees. Written informed consent was obtained from each patient prior to surgery. 
Simultaneous measurements of force production and ATPase activity
The solutions and equipment used for the functional measurements, have been described previously. 24, 25 Membrane-permeabilized cardiac muscle strips were stretched in the apparatus based on the passive force reaching 10% of the maximal calcium-activated force, which corresponds to a sarcomere length of ~2.2 μm. until it reached a steady state and subsequently relaxed in a low [Ca 2+ ] solution (pCa 9; 1 nmol•L -1 ) ( Figure 1A ). Force was determined at the steady state level and was normalized to the cross-sectional area (CSA) of the muscle strip to calculate tension. The CSA of the preparation was estimated based on an elliptical shape, i.e. CSA = (width x depth x π)/4. Average dimensions (mean±SD) of all muscle strips (n=118) were 1.4±0.4 mm in length, 352±60 μm in width and 309±55 μm in depth. ATPase activity was measured using an enzyme coupled assay in which ATP regeneration from ADP and phosphoenol-pyruvate by the enzyme pyruvate kinase is coupled with the oxidation of NADH to NAD + and the reduction of pyruvate to lactate by Llactic dehydrogenase and was normalized to volume (length x CSA). 27 NADH oxidation ( Figure 1B ) was measured photometrically from the absorbance at 340 nm of near-UV light. When the muscle strip was transferred into the activation solution, force developed and the NADH absorbance signal started to decline simultaneously. After returning the muscle strip into the relaxation solution, 0.5 nmol ADP was injected into the measuring bath to calibrate the absorbance signal. The Ca 2+ -activated ATPase activity was calculated using the slope of the dotted regression line fitted to the absorbance signal when it reached a steady state. The resting ATPase activity was subtracted from the maximal ATPase activity at each [Ca 2+ ]. Resting ATPase activity was measured in relaxing solution (pCa 9.0). The economy of muscle contraction is expressed as TC, i.e. the amount of ATP used during the development of force (normalized to CSA). In vivo analysis Pre-hypertrophic mutation carriers This study population comprised 28 asymptomatic pre-hypertrophic mutation carriers.
Mutation carriers were first-degree relatives of symptomatic HCM patients and were recruited after genetic testing. Fourteen carriers had a mutation in MYBPC3 and 14 in MYH7. The LV wall thickness in all subjects was less than 10 mm. None of the carriers had systemic or other cardiac disease or used medication. In addition, 14 genotype-negative relatives of the mutation carriers were included as a control group. The study was approved by the Medical Ethics Review Committee of the VU University Medical Center and all participants gave written informed consent prior to inclusion.
CMR and PET
The study protocol comprised [ 11 C]-acetate PET and CMR imaging.
CMR image acquisition
CMR was performed on a 1.5-Tesla whole body scanner (Magnetom Sonata or Avanto, Siemens, Erlangen, Germany), using a six-channel phased-array body coil. After survey scans, a retro-triggered, balanced steady-state free precession gradient-echo sequence was used for cine imaging. Image parameters were: slice thickness 5 mm, slice gap 5 mm, temporal resolution <50 ms, repetition time 3.2 ms, echo time 1.54 ms, flip angle 60°a nd a typical image resolution of 1.3 by 1.6 mm. The cardiac cycle consisted of 20 phases. After obtaining 4-, 3-, and 2-chamber view cines, a contiguous short-axis steady-state free precession stack was acquired extending from the mitral valve annulus to the LV apex, to obtain LV mass (LVM) and enable volumetric analysis of the LV. 28 Cine images were acquired during breath-hold at mild expiration. Late gadolinium enhancement (LGE) images were acquired 10-15 minutes after intravenous administration of 0.2 mmol•kg -1 gadolinium, using a two-dimensional segmented inversion-recovery prepared gradient-echo sequence. Inversion-recovery time was 250-300 ms.
CMR image analysis
Images were analysed off-line using the software package MASS (MR Analyical Software System; Medis, Leiden, The Netherlands). LV volume analysis was performed by manually drawing epicardial and endocardial contours on all end-diastolic (ED) and end-systolic (ES) LV short-axis images. Next, global LV function parameters, including ED volume (LVEDV), ES volume (LVESV), stroke volume (SV), LV ejection fraction (LVEF) and LV mass (LVM) were computed from the cine images. Each myocardial segment was evaluated for the presence of hyper enhancement, i.e.
LGE, which is a measure of replacement fibrosis, defined as an area of signal enhancement greater than 5 SD of the signal of non-enhanced myocardium. The extent of LGE was expressed as the percentage of the total myocardial tissue area studied. Cardiac mechanical external work (EW) was calculated as the product of stroke volume and mean arterial pressure. . To correct for attenuation and scatter, the emission scan was followed immediately by a slow, respiration-averaged low dose CT scan (LD-CT, 55 mAs, rotation time 1.5 s, pitch 0.825, collimation 64x0.625, acquiring 20 cm in 12 s) during normal breathing. Data were reconstructed into 36 successive time frames (1x10, 8x5, 4x10, 3x20, 5x30, 5x60, 4x150, 6x300 s). Blood pressure and heart rate were recorded at regular intervals throughout the imaging procedures. Before PET acquisition, venous blood was withdrawn and NH 2 -terminal pro-brain natriuretic peptide (NT-proBNP,), haemoglobin (Hb), creatinine, glucose, free fatty acid (FFA) and lactate levels were determined.
PET/CT image acquisition
PET/CT image analysis
Input functions were obtained using in-house developed software. One cm diameter regions of-interest (ROIs) were placed over the ascending aorta in at least 5 trans axial image planes of the frame showing the first pass of the injected bolus. These ROIs were combined into one volume of interest (VOI) for the ascending aorta. A second set of ROIs was placed over the right ventricular (RV) cavity in 5 trans axial planes, with ROI boundaries at least 1 cm from the RV wall to avoid spill-over of myocardial activity. These ROIs were similarly combined into one RV VOI. Both VOIs were then transferred to the full dynamic images to obtain arterial whole blood (C A (t)) and RV (C RV (t)) time-activity curves. A correction for the fraction of non-metabolized [ 11 C]-acetate was applied to C A (t), based on data published by Sun and co-workers. 29 Images were reoriented to short-axis images and 17 myocardial segments were defined on images of tracer uptake between 5-10 minutes post injection. Obtained segment templates were projected onto all frames of the dynamic emission scan to extract segmental timeactivity curves, which were fitted using a single tissue compartment model. 30 The rate constant k 2 , representing the rate of transfer of radioactivity from tissue to blood, was used to derive myocardial oxygen consumption (MVO 2 ) as described previously.
29
Myocardial efficiency
The combination of PET-derived MVO 2 and CMR-derived mechanical EW enables calculation of myocardial (external) efficiency as follows,
in which HR is the heart rate and the constants represent the caloric equivalent of 1 mmHg•mL EW, which is 1.33•10 -4 J, whereas 1 mL O 2 corresponds to 20 J.
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Accuracy and reproducibility of PET/CMR analyses
The combination of PET/CMR analyses allow non-invasive determination of myocardial efficiency, which is the ratio of cardiac work and MVO 2 . 31 Accurate measurement of left ventricular (LV) volumes is important for the assessment of cardiac work. Cardiac CMR is considered the gold standard technique for LV volume measurements, because of the excellent accuracy and reproducibility of this technique. 32, 33 In order to test the reproducibility of both imaging modalities in our study, three patients per group were randomly selected and PET/CMR images were analyzed by two operators independently from each other. The intra-and inter-observer agreements of different PET/CMR parameters were high ( Table 2) . Two different PET scanners were used to obtain values for k 2 for the MYBPC3 mut carriers previously 23 , and for the MYH7 mut carriers. When comparing data from different scanners linearity issues and partial volume effects should be kept in mind. We have carefully checked these two parameters in previous studies. Regarding linearity issues, care was taken to ensure that the injected dose was within the linear range of the scanners used for both groups. For the controls and MYBPC3 mut carriers, activity was half of that typically used for 15 O-water scans in these patients, ruling out linearity issues. For the MYH7 mut group, dose was confirmed to be within the linear range of the scanner as confirmed in an earlier study using this scanner. 34 With respect to partial volume effects, the regions of interest (ROIs) in the aorta were 10 mm in diameter, whilst the aorta itself is typically~25 mm in diameter. By placing the ROIs in the center of the aorta, partial volume effects are expected to be negligible as the ROIs were placed at least 8 mm from the edge of the aorta. Myocardial ROIs can suffer from partial volume effects, but these effects will only affect the absolute scaling of the time-activity curves, not the shape. Since we are evaluating k 2 i.e. washout of activity from tissue, absolute scaling plays no role in our estimation of k 2 , as k 2 is estimated from the shape of the curve, not the height. This has been confirmed in an earlier study for 15 O-water, a tracer for which washout rate is the parameter of interest, as well. 35 In order to keep the same scanning conditions, a standardized protocol was used for both imaging techniques. To reduce confounding effects on MVO 2 , all PET-acquisitions were performed after overnight fasting of patients. Finally, we have proven experience with measurements of myocardial efficiency in HCM and carriers.
23,36,37 
Statistics
Data analysis and statistics were performed using Prism version 5.0 (Graphpad Software, Inc., La Jolla, CA, USA) and SPSS version 20.0 (IMB, Armonk, NY, USA). The data regarding in vitro studies on myocardial tissue samples from manifest HCM patients are expressed as mean±SD. N is the number of patients and n is the number of measured muscle strips. The data sets (MYBPC3 mut , MYH7 mut and HCM smn ) were tested for normality using the Shapiro-Wilk test. Normality was assumed when P>0.05 and variances were equal. The data sets regarding tension and ATPase activity were not violating this normality assumption, whereas TC data sets at both maximal and submaximal [Ca 2+ ] did. For this purpose, TC data sets had to be logarithmically transformed, which led to data sets following the normal distribution. As repeated sample assessments needed to be taken into account (multiple muscle strips were measured from one patient), multilevel analysis was performed using a linear mixed model procedure (SPSS) to investigate differences amongst groups. 38, 39 All analyses were performed on the individual measured muscle strips per data set. Data regarding phenotype-negative HCM mutation carriers were expressed by mean±SD. Statistics was performed on the individual patients. The data sets (MYBPC3 mut , MYH7 mut and controls) were tested for normality as well using the Shapiro-Wilk test. The normality assumption was not violated (P>0.05). A one-way ANOVA with Bonferroni post-hoc test was performed to investigate differences amongst groups. P<0.05 was considered significant.
Results
Characteristics of manifest HCM patients
Patient characteristics are shown in Table 1 . Hypertrophic obstructive cardiomyopathy was evident from septal thickness ≥15 mm 40 and high LV outflow tract pressure gradient (normal value <30 mmHg). 41 There were no significant differences regarding the demographic and clinical parameters amongst the three manifest patient groups. The mutations present in the MYBPC3 mut group are all so-called truncating mutations. Previous studies showed that truncating mutations result in a reduced expression of full length cMyBP-C (i.e. haploinsufficiency). 42, 43 The mutations present in the MYH7 mut group are all missense mutations leading to poison peptides. 44 
Tension, ATPase activity and tension cost
Force production and ATPase activity were simultaneously measured in tissue of 11 MYBPC3 mut , 9 MYH7 mut and 6 HCM smn patients. (Figure 2A ). Figure 2B shows that maximal ATPase activity did not differ between MYBPC3 mut and HCM smn , but it was significantly lower in MYH7 mut compared with both MYBPC3 mut ( # P<0.0001) and HCM smn ( *
P=0.003).
The ratio between maximal ATPase activity and tension represents the energetic cost of tension generation ( Figure 2C ). The normality assumption was violated (p<0.05), hence this data set needed to be logarithmically transformed before multilevel analysis could be performed. TC in MYH7 mut was significantly higher than in HCM smn ( * P<0.0001). Moreover, TC was significantly higher in MYH7 mut than in MYBPC3 mut ( #
P=0.01).
Measurements of tension and ATPase activity were also performed at sub-maximal [Ca 2+ ] to assess TC in the physiologic range of [Ca 2+ ]. The relation between tension and ATPase activity over the entire range of [Ca 2+ ] can be fitted to a linear equation. 45 The slope of the ATPase activity-tension curve represents TC over the entire [Ca 2+ ] range as can be appreciated from Figure 2D . The vertical intercept represents ATPase activity at baseline. This resting ATPase activity did not significantly differ among MYBPC3 mut , MYH7 mut and HCM smn (6.8±1.0, 4.5±0.8 and 7.5±2.5 μmol•L -1 •s -1 , respectively). The individual slopes of all muscle strips were averaged per group and are shown in Figure 2E . This data set violated the normality assumption (P<0.05), therefore requiring logarithmical transformation. Compared with HCM smn the slope was significantly higher in MYH7 mut ( * P=0.009). In addition, the slope of MYH7 mut was also higher compared with MYBPC3 mut ( # P=0.036). Overall, data indicate that ATPase activity for force development is higher in mutation-positive than in mutationnegative preparations. The magnitude of the decrease in economy of sarcomere contraction depends on the affected gene at both saturating and sub-saturating calcium concentrations. ]. E. The average slopes of the ATPase activitytension relations in MYBPC3 mut , MYH7 mut and HCM smn
Characteristics of pre-hypertrophic mutation carriers and controls
A total of 28 asymptomatic pre-hypertrophic mutation carriers and 14 genotype-negative relatives were included in the study. The pre-hypertrophic MYBPC3 mutation carriers all harbor the truncating mutation c.2373dupG, which was also present in samples from 2 manifest HCM patients (Table 1) . Although the mutations present in pre-hypertrophic mutation carriers (Table 3 ) and in manifest HCM patients (Table 1) were not exactly the same, the type of mutation was similar in both groups as all MYBPC3 mutations were truncating mutations and MYH7 mutations were missense mutations. Average characteristics of the groups are provided in Table 2 . The LVM index was comparable between MYBPC3 mut , MYH7 mut and controls, as was stroke volume index and LV ejection fraction. No differences were observed with respect to end-diastolic wall thickness (both septal and lateral walls, Table 2 ) between groups. Moreover, myocardium of all subjects displayed no late gadolinium enhancement.
Haemodynamic and metabolic characteristics, obtained during [ 11 C]-acetate PET acquisition, of the groups are depicted in Table 4 . Blood pressure, heart rate and rate pressure product were significantly lower in MYH7 mut than in controls. Mean arterial pressure was significantly lower in MYH7 mut than in MYBPC3 mut . Fasting glucose, free fatty acids, lactate, hemoglobin and NT-proBNP were comparable between groups. Figure 3 shows representative CMR and [ 11 C]-acetate PET images of the 3 separate groups. No structural differences were present between groups, as can be seen on the modified 4-chamber views. K 2 , representing the rate of [ 11 C]-acetate washout, tended to be higher in both mutation carrier groups, indicating a higher oxygen consumption. It did not significantly differ from controls. LGE, late gadolinium enhancement. 
Discussion
We performed a comprehensive investigation of the impact of sarcomere mutations on energetic cost of cardiac contraction. By encompassing observations at the level of the myocardium to the level of the intact human, it was demonstrated that impaired energetic efficiency appears to be a fundamental consequence of sarcomere mutations. In vitro measurements of tension and ATPase activity in human cardiac muscle strips revealed a higher TC in sarcomere mutation-positive compared with sarcomere mutation-negative HCM. This suggests that energetic alterations are primarily related to the sarcomere mutation itself, rather than a non-specific feature of hypertrophied myocardium. TC of sarcomere contraction was highest in myocardium harboring mutations in MYH7 compared with MYBPC3. Furthermore, non-invasive quantification of myocardial efficiency by use of [ 11 C]-acetate PET and CMR imaging in pre-hypertrophic mutation carriers revealed a significantly lower myocardial efficiency in both MYH7 mut and MYBPC3 mut compared with controls. The present results provide evidence that sarcomere mutations perturb the energetics of cardiac contractility in human myocardium. The reduction in myocardial efficiency was more prominent in the MYH7 mut than in the MYBPC3 mut group, at both the pre-hypertrophic and advanced stage of the disease and may underlie differences observed in disease onset between these groups. These findings imply that the increase in the energetic cost of sarcomere contraction depends on the affected gene. In addition, detection of reduced myocardial efficiency in prehypertrophic individuals carrying a sarcomere mutation suggests a potential target for treatment at an early stage of HCM disease.
Contractile function
Permeabilized cardiac multicellular muscle strips from manifest HCM-patients with MYBPC3 or MYH7 mutations showed significantly lower maximal tension development compared with muscle strips from patients without sarcomere mutations. This is in line with the previously found decrease in maximal tension in single human cardiac cells harboring MYBPC3 and MYH7 mutations compared with non-failing donor cardiomyocytes. 39, 42, [46] [47] [48] The decrease in maximal tension was most prominent in MYH7 mut muscle (Figure 2A ). In accordance with the in vitro measurements of force development in cardiac muscle strips, in vivo EW was significantly lower in both pre-hypertrophic mutation carrier groups compared with healthy controls, and the reduction in cardiac work was more prominent in MYH7 mut than in MYBPC3 mut ( Figure 4A ). Overall, these data suggest that mutations in thick filament proteins reduce the force generating capacity of the myocardium even before the development of hypertrophy.
Cardiac energy utilization
ATPase activity in MYBPC3 mut did not differ compared with HCM smn and was lowest in MYH7 mut . Although no increase was observed in ATPase activity in sarcomere mutationpositive myocardium compared with sarcomere mutation-negative samples, TC was significantly increased in both MYH7 mut and MYBPC3 mut compared with HCM smn . The increase in TC, explained primarily by a reduction in maximal force generating capacity, was largest in HCM caused by MYH7 mutations.
The present data show for the first time that energetic cost of contraction is increased due to an imbalance between force generating capacity and ATPase activity in sarcomere mutation-positive human HCM myocardium. Our findings are in line with previous results using similar measurements of ATPase activity and force development in muscle strips from transgenic mouse models harboring mutations in TNNT2. 49, 50 In these mouse models the increase in TC in mice with a TNNT2 mutation was explained by a significant decrease in force production and no change 49 or only a minor increase 50 in ATPase activity. The observation that changes in energetic cost of contraction are mostly due to a drop in force generating capacity is supported by a previous in vitro motility and ATPase assay in human HCM tissue with a MYH7 mutation. It was found that actin sliding velocity lagged behind ATPase activity. 51 In addition, an in vitro functional study 52 confirmed a higher rate of actin-myosin dissociation in skinned myofibrillar preparations harboring a MYH7 mutation, which relates to a drop in force production and increased energetic cost of contraction. 53, 54 Different parameters were determined within our in vitro analysis of local sarcomere energetics (ATPase activity and isometric tension) and in vivo analysis of global myocardial energetics (oxygen consumption and cardiac work production) to assess efficiency of cardiac performance. Nevertheless, in accordance with our in vitro analysis of TC, studies in prehypertrophic MYH7 mut carriers showed a more severe reduction in myocardial efficiency compared with MYBPC3 mut carriers ( Figure 4C ). The decrease in myocardial efficiency was largely explained by a reduction in cardiac work rather than an increase in MVO 2. To date, only a few non-invasive in vivo studies of myocardial energetics in genotype-positive, phenotype-negative mutation carriers have been performed. 20, 23 A study by Crilley et al.
showed that PCr/ATP was reduced in phenotype-negative mutation carriers as well. 20 However, no distinction could be made between carriers with different gene-mutations due to the small numbers. Another study demonstrated that alterations in PCr/ATP in HCM are correlated with the presence of fibrotic areas in the myocardium. 55 In the present study, however, patients underwent late gadolinium enhancement imaging to rule out the presence of replacement fibrosis. Overall, our in vitro results using tissue of phenotype-positive HCM subjects, revealed an increase in TC based on a misbalance between force generating capacity and ATPase activity. Therefore it could be one of the mechanisms for global myocardial deficiency. Already in an early pre-hypertrophic phase of HCM, sarcomere mutations lead to a decrease in global myocardial efficiency as there is less work produced while there is no change in energy utilization compared with healthy controls. Therefore, our in vivo findings suggest that disturbance of myocardial efficiency is indeed a primary event before onset of cardiac remodelling. Disturbances in myocardial energetics seem to be more prominent in HCM with MYH7 compared with MYBPC3 mutations and may explain the difference in disease onset between these two groups.
Study limitations
Myocardial ischemia has been associated with alterations of myocardial metabolism and may also influence myocardial efficiency. In the present study, no measurements of myocardial perfusion were performed in both phenotype-negative carrier groups and healthy controls to rule out myocardial ischaemia. On the other hand, patients were considered to be at low risk for coronary artery disease based on clinical history and ECG findings. No regional wall motion abnormalities were seen on CMR. Furthermore, there was no fibrosis present as demonstrated by late gadolinium enhancement imaging (Table 3) . The number of patients included in this study was relatively small, and therefore, results should be interpreted with care. Nonetheless, group sample sizes were large enough to provide evidence of mutation-specific abnormalities in myocardial energetic cost of contraction in human HCM. In the in vivo imaging study, groups were not matched for ageand gender. Pre-hypertrophic mutation carriers were significantly younger and more women were included compared with the control group. However, based on the fact that myocardial energetics deteriorates with aging 56, 57 , the reduction in myocardial efficiency observed in mutation carriers would be even larger when compared to age-matched controls.
Clinical implications
The present results show that sarcomere energetics is affected mostly in HCM with MYH7 mutations, in the manifest stage of the disease. Moreover, MYH7 mutations seem to results in a more severe clinical phenotype than in MYBPC3 mutations as septal thickness was slightly higher in MYH7 mut compared with MYBPC3 mut HCM patients (Table 1) . However, patients with the same MYH7 mutation showed a diverse disease onset as a 28-year old patient with the c.2080C>T mutation had the highest septal thickness (49 mm), while another patient with the same mutation was operated at 81 years of age. Strikingly, septal thickness in this older patient was only 19 mm (Table 1) . Recently a pharmacological intervention study 58 was performed in HCM patients using perhexiline, a modulator of substrate metabolism, shifting metabolism from free fatty acids to glucose. 59 Perhexiline treatment improved myocardial energetics and exercise capacity. The present results show that disturbance in myocardial efficiency is already present in pre-hypertrophic mutation carriers and may be a primary trigger for the development of the HCM phenotype. Both in vivo at the pre-hypertrophic stage and in vitro in manifest HCM, the present study provides evidence that the degree of impaired efficiency of contraction depends on the affected gene. These data warrant further clinical studies towards gene-specific metabolic treatment at an early phase of the disease process.
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